Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Joshua M. Hare
Joshua M. Hare, Miami Beach, FL US
| Patent application number | Description | Published |
|---|---|---|
| 20090274687 | ATTENUATION OF HYPOXIA INDUCED CARDIOVASCULAR DISORDERS - Blockade of stromal derived factor-1 (SDF-1), a stem cell mobilizer and/or its receptor, chemokine receptor 4 (CXCR4) attenuates and reverses hypoxia-induced cardiopulmonary remodeling in vivo. Compositions for treating hypoxia-induced cardiovascular disorders modulate the SDF-1/CXCR4 axis. | 11-05-2009 |
| 20100112587 | TRANSCRIPTOMIC BIOMARKERS FOR INDIVIDUAL RISK ASSESSMENT IN NEW ONSET HEART FAILURE - A novel transcriptomic biomarker for prognosis in heart failure has a direct clinical application in prediction of prognosis in new onset heart failure, heart disease, heart disorders and associated heart conditions. This approach should improve individualization of cardiac care and help identify patients at highest risk for circulatory collapse within the first years of presentation with heart failure. | 05-06-2010 |
| 20100190650 | TRANSCRIPTOMIC BIOMARKER OF MYOCARDITIS - Molecular signatures that function as very sensitive diagnostic biomarker for myocarditis, heart disease and disorders thereof, are identified. | 07-29-2010 |
| 20100310532 | GENE TARGETS IN ANTI-AGING THERAPY AND TISSUE REPAIR - Novel gene and protein targets are described for treatment of cardiac disorders, anti-aging therapies and tissue repair. Identified biomarkers are prognostic of long term survival of patients suffering from heart diseases and related disorders. | 12-09-2010 |
| 20100316622 | DIAGNOSIS AND TREATMENT OF CARDIAC DISORDERS - Nitric oxide synthase deficiency causes diminished ryanodine receptor S-nitrosylation leading to increased diastolic calcium (Ca | 12-16-2010 |
Joshua M. Hare, Baltimore, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20090298912 | Arginase II: A Target treatment of aging heart and heart failure - The instant invention provides methods and compositions for the treatment of cardiac dysfunction. Specifically, the invention provides methods and compositions for modulating Arginase II for the treatment of cardiac dysfunction. | 12-03-2009 |
| 20090305295 | IDENTIFICATION OF A GENE EXPRESSION PROFILE THAT DIFFERENTIATES ISCHEMIC AND NONISCHEMIC CARDIOMYOPATHY - A method of preparing a gene expression prediction profile for distinguishing ischemic and nonischemic cardiomyopathy comprises the steps of obtaining clinical specimens from patients suffering from ischemic or nonischemic cardiomyopathy, isolating nucleic acid sequences from at least a plurality of said specimens, obtaining a gene expression level corresponding to each individual of said nucleic acid sequence by a gene expression profiling method, identifying genes having differences in gene expression by comparing the gene expression level of an ischemic specimen with the gene expression level of a nonischemic specimen, and identifying a gene expression prediction profile comprises genes identified as having differences in gene expression so that said prediction profile distinguishes ischemic and nonischemic cardiomyopathy. | 12-10-2009 |
| 20100010019 | Reactive Oxygen Generating Enzyme Inhibitor With Nitric Oxide Bioactivity and Uses Thereof - A reactive oxygen generating enzyme inhibitor with NO donor bioactivity, e.g., nitrated allopurinol, is useful to treat heart failure, stable angina, ischemic disorder, ischemic reperfusion injury, atherosclerosis, sickle cell disease, diabetes, Alzheimer's disease, Parkinson's disease, ALS and asthma and to obtain proper contraction of heart, skeletal and smooth muscle. | 01-14-2010 |
Joshua M. Hare, Miami, FL US
| Patent application number | Description | Published |
|---|---|---|
| 20110159487 | Identification of a Gene Expression Profile that Differentiates Ischemic and Nonischemic Cardiomyopathy - A method of preparing a gene expression prediction profile for distinguishing ischemic and nonischemic cardiomyopathy comprises the steps of obtaining clinical specimens from patients suffering from ischemic or nonischemic cardiomyopathy, isolating nucleic acid sequences from at least a plurality of said specimens, obtaining a gene expression level corresponding to each individual of said nucleic acid sequence by a gene expression profiling method, identifying genes having differences in gene expression by comparing the gene expression level of an ischemic specimen with the gene expression level of a nonischemic specimen, and identifying a gene expression prediction profile comprises genes identified as having differences in gene expression so that said prediction profile distinguishes ischemic and nonischemic cardiomyopathy. | 06-30-2011 |